This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Edodekin alfa
- DrugBank Accession Number
- DB15631
- Background
Edodekin alfa is under investigation in clinical trial NCT01468896 (Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery).
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Interleukin-based products - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Edodekin alfa
- Human il-12 (recombinant)
- Interleukin 12 (human)
- Interleukin-12, human
- Recombinant Human Interleukin-12
- Recombinant interleukin-12
- External IDs
- Ro 24-7472
- RO 24-7472/000
- RO-24-7472
- RO-24-7472/000
- RO-247472000
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAmbroxol The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Articaine. Benzocaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Benzyl alcohol. Bupivacaine The risk or severity of methemoglobinemia can be increased when Edodekin alfa is combined with Bupivacaine. - Food Interactions
- Not Available
Categories
- Drug Categories
- Adjuvants, Immunologic
- Amino Acids, Peptides, and Proteins
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Antineoplastic Agents
- Biological Factors
- Cytokines
- Growth Inhibitors
- Growth Substances
- Immunologic Factors
- Intercellular Signaling Peptides and Proteins
- Interleukin-12, antagonists & inhibitors
- Interleukins
- Peptides
- Proteins
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 31Z82G8ME1
- CAS number
- 187348-17-0
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created at March 07, 2020 20:05 / Updated at January 14, 2023 19:02